BioPharmSignal logoBioPharmSignal

Biotech News

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Enanta Pharmaceuticals (ENTA)Enanta PharmaceuticalsConference / presentation

WATERTOWN, Mass. --(BUSINESS WIRE)--May 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation

Open original release

Related news

ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

KYMRKymera2026-05-15 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

BCRXBioCryst Pharmaceuticals2026-05-13 11:00 EST

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

BCRXBioCryst Pharmaceuticals2026-04-28 11:00 EST

BioCryst to Present at Upcoming Investor Conferences

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

NRIXNurix Therapeutics2026-05-12 20:05 EST

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

ARGXArgenx2026-05-06 20:30 EST

argenx to Present at BofA Securities 2026 Health Care Conference

View all latest news

Enanta Pharmaceuticals

Enanta Pharmaceuticals is a small-molecule company with a history in antiviral research and a newer focus on immunology and respiratory disease. The story has shifted from pure antiviral discovery to a broader pipeline reset.

Recent company news

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

ENTAEnanta Pharmaceuticals2026-04-07 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

Stock data

Close
12.73 USD
Market cap
349.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States